LCZ696 (Valsartan/Sacubitril) - A Possible New Treatment for Hypertension and Heart Failure.
Århus, Denmark. In Basic Clin Pharmacol Toxicol, Jan 2016
The aim of this MiniReview was to introduce the newly invented dual-acting drug valsartan/sacubitril (LCZ696), which combines an angiotensin receptor blocker (valsartan) with sacubitril, a specific inhibitor of the neutral endopeptidase (NEP) that degrades vasoactive peptides, including natriuretic peptides ANP and BNP, but also glucagon, enkephalins and bradykinin, among others.
Neuroendocrine control of body fluid metabolism.
Ribeirão Preto, Brazil. In Physiol Rev, 2004
Since the discovery of the atrial natriuretic peptide (ANP), a large number of publications have demonstrated that this peptide provides a potent defense mechanism against volume overload in mammals, including humans.